SIAIS178 (ip; 5, 15, and 45 mg/kg; 12 days) attenuates tumor progression in a dose-dependent manner, as determined by serial volumetric measurement [1].
SIAIS178 (iv or ip; 2 mg/kg; 24 hours) has T1/2 of 3.82 and 12.35 hours and Cmax of 1165.2 nM and 30 nM for iv and ip, respectively[1].
| Animal Model: | NOD/SCID mice with termed K562-Luc[1] |
| Dosage: | 5, 15, and 45 mg/kg |
| Administration: | Ip; 12 days |
| Result: | Attenuated tumor progression in a dose-dependent manner, as determined by serial volumetric measurement.
|
| Animal Model: | Female Wistar rats[1] |
| Dosage: | 2 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Iv or ip; 24 hours |
| Result: | Had T1/2 of 3.82 and 12.35 hours and Cmax of 1165.2 nM and 30 nM for iv and ip, respectively.
|
